Modality
Cell Therapy
MOA
CD47i
Target
JAK2
Pathway
Autophagy
LNPsoriasisRSV
Development Pipeline
Preclinical
~Aug 2011
→ ~Nov 2012
Phase 1
~Feb 2013
→ ~May 2014
Phase 2
~Aug 2014
→ ~Nov 2015
Phase 3
~Feb 2016
→ ~May 2017
NDA/BLA
Aug 2017
→ Nov 2028
NDA/BLACurrent
NCT06235307
1,718 pts·Psoriasis
2023-08→TBD·Completed
NCT08594730
2,237 pts·RSV
2017-08→2028-11·Active
3,955 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-11-288mo awayEnrollment Complete· Psoriasis
2028-11-062.6y awayPh3 Readout· RSV
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Active
NDA/BLA
Complet…
Catalysts
Enrollment Complete
2026-11-28 · 8mo away
Psoriasis
Ph3 Readout
2028-11-06 · 2.6y away
RSV
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06235307 | NDA/BLA | Psoriasis | Completed | 1718 | UPCR |
| NCT08594730 | NDA/BLA | RSV | Active | 2237 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |